Dear Colleagues, dear Guests,
Following the first meeting in Utrecht, Netherlands, and the second in
Toronto, Canada, the Tübingen team took up the challenge of hosting
the third International Consensus Meeting on Robin Sequence (RS) in
As true for many rare conditions, treatment approaches for RS vary
considerably, as randomized controlled trials are difficult to perform.
Evidence for different treatments, however, can also be based on
cohort studies. This requires agreement on the relevant outcomes
tested in such studies, i.e. the definition of a common data set to be
used in future clinical studies on RS.
The latter will be the main subject during the upcoming 3rd
international RS meeting. We expect renowned speakers from around
the world to present their latest data with a focus on a quantification of
sleep-related upper airway obstruction and failure to thrive as the two
most relevant early outcomes in RS. Also, is there mandibular catch-up
growth in RS? What is the long-term outcome and quality-of-life after
the various interventions used, and what do parents think?
Whichever approach is being taken, RS treatment requires a team
approach, and this is not only reflected by our organizing committee,
but also by the faculty of this meeting.
Tübingen is an old medieval university town (the university was
founded in 1492) located in Germany's beautiful South-West, where
weather conditions can already be quite pleasant in April (but wet and
cold weather conditions are also possible).
We are looking forward to welcoming you to Tübingen!